Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Depreciation & Amortization (CF) (2021 - 2025)

SAB Biotherapeutics' Depreciation & Amortization (CF) history spans 5 years, with the latest figure at $746830.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 7.31% year-over-year to $746830.0; the TTM value through Dec 2025 reached $3.0 million, down 36.18%, while the annual FY2025 figure was $3.0 million, 36.25% down from the prior year.
  • Depreciation & Amortization (CF) reached $746830.0 in Q4 2025 per SABSW's latest filing, up from $700000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $2.0 million in Q1 2024 to a low of $235959.0 in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $808363.9, with a median of $802885.5 recorded in 2024.
  • Peak YoY movement for Depreciation & Amortization (CF): surged 189.7% in 2022, then crashed 62.17% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $619984.0 in 2021, then surged by 45.07% to $899429.0 in 2022, then increased by 11.18% to $1.0 million in 2023, then fell by 19.42% to $805771.0 in 2024, then fell by 7.31% to $746830.0 in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Depreciation & Amortization (CF) are $746830.0 (Q4 2025), $700000.0 (Q3 2025), and $800000.0 (Q2 2025).